These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 26161698)

  • 1. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors closer to market launch?
    Galons H; Oumata N; Gloulou O; Meijer L
    Expert Opin Ther Pat; 2013 Aug; 23(8):945-63. PubMed ID: 23600454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
    Galons H; Oumata N; Meijer L
    Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA; Pentimalli F; Esposito L; Giordano A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
    Law ME; Corsino PE; Narayan S; Law BK
    Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
    DiPippo AJ; Patel NK; Barnett CM
    Pharmacotherapy; 2016 Jun; 36(6):652-67. PubMed ID: 27087139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
    Whittaker SR; Mallinger A; Workman P; Clarke PA
    Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.
    Vymětalová L; Kryštof V
    Med Res Rev; 2015 Nov; 35(6):1156-74. PubMed ID: 26114963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibitors as anticancer drugs.
    Krystof V; Uldrijan S
    Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.